

**CFH Antibody (Center) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP10942c****Specification**

---

**CFH Antibody (Center) Blocking peptide - Product Information**Primary Accession [P08603](#)**CFH Antibody (Center) Blocking peptide - Additional Information****Gene ID** 3075**Other Names**

Complement factor H, H factor 1, CFH, HF, HF1, HF2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CFH Antibody (Center) Blocking peptide - Protein Information****Name** CFH**Synonyms** HF, HF1, HF2**Function**

Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Acts as a soluble inhibitor of complement, where its binding to self markers such as glycan structures prevents complement activation and amplification on cell surfaces (PubMed: [21285368](http://www.uniprot.org/citations/21285368), PubMed: [25402769](http://www.uniprot.org/citations/25402769)). Accelerates the decay of the complement alternative pathway (AP) C3 convertase C3bBb, thus preventing local formation of more C3b, the central player of the complement amplification loop (PubMed: [19503104](http://www.uniprot.org/citations/19503104), PubMed: [26700768](http://www.uniprot.org/citations/26700768)). As a cofactor of the serine protease factor I, CFH also regulates proteolytic degradation of already-deposited C3b (PubMed: [23332154](http://www.uniprot.org/citations/23332154), PubMed: [18252712](http://www.uniprot.org/citations/18252712), PubMed: [28671664](http://www.uniprot.org/citations/28671664)). In addition, mediates several cellular responses through interaction with specific receptors. For example, interacts with CR3/ITGAM receptor and thereby mediates the adhesion of human neutrophils to

different pathogens. In turn, these pathogens are phagocytosed and destroyed (PubMed:<a href="http://www.uniprot.org/citations/9558116" target="\_blank">9558116</a>, PubMed:<a href="http://www.uniprot.org/citations/20008295" target="\_blank">20008295</a>).

#### **Cellular Location**

Secreted.

#### **Tissue Location**

Expressed in the retinal pigment epithelium (at protein level) (PubMed:25136834). CFH is one of the most abundant complement components in blood where the liver is the major source of CFH protein in vivo. In addition, CFH is secreted by additional cell types including monocytes, fibroblasts, or endothelial cells (PubMed:6444659, PubMed:2968404, PubMed:2139673, PubMed:25136834)

### **CFH Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **CFH Antibody (Center) Blocking peptide - Images**

### **CFH Antibody (Center) Blocking peptide - Background**

This gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation, restricting this innate defense mechanism to microbial infections. Mutations in this gene have been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

### **CFH Antibody (Center) Blocking peptide - References**

Dieterich, R., et al. Infect. Immun. 78(11):4467-4476(2010) Sofat, R., et al. Atherosclerosis 213(1):184-190(2010) Davila, S., et al. Nat. Genet. 42(9):772-776(2010) Scambi, C., et al. PLoS ONE 5 (8), E12162 (2010) :Bunkenborg, J., et al. Proteomics 4(2):454-465(2004)